Online inquiry

IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6709MR)

This product GTTS-WQ6709MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6709MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5684MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ6096MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ5515MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ13434MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ8001MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ198MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ5703MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ3125MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA APN311
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW